Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10310477 | 0.80 | TP53 (0.39) | GRM7CREBBPTP53PIP4K2AKDR | |
| SCHEMBL29766049 | 0.79 | MAOB (0.36) | TP53PIP4K2ANPC1RAB9AKDM4E | |
| SCHEMBL23115842 | 0.79 | MAOB (0.36) | TP53PIP4K2ANPC1RAB9AKDM4E | |
| SCHEMBL23302207 | 0.79 | CCR4 (0.39) | RAB9AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL18963841 | 0.79 | NPC1 (0.31) | NPC1RAB9A | |
| SCHEMBL29769114 | 0.77 | PIP4K2A (0.38) | GRM7CREBBPTP53PIP4K2AKDR | |
| SCHEMBL13676392 | 0.77 | PIP4K2A (0.38) | GRM7CREBBPTP53PIP4K2AKDR | |
| SCHEMBL30861058 | 0.77 | PI4KA (0.38) | GRM7CREBBPTP53KDM4EALDH1A1 | |
| SCHEMBL21608562 | 0.77 | PI4KA (0.38) | GRM7CREBBPTP53KDM4EALDH1A1 | |
| SCHEMBL15518859 | 0.77 | BRD4 (0.36) | CREBBPTP53NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11446298-B2 | Pyrimidine derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-2855419-B1 | NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-8633182-B2 | Indanyloxyphenylcyclopropanecarboxylic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20130324514-A1 | INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324514-A1 | INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS | GPR119, GPR65, INSR | GRM7 1085/4885CREBBP 1292/4885TP53 4062/4885 |
| US-11446298-B2 | Pyrimidine derivatives | PTGER1, PTGER4, PTGER2 | GRM7 2801/4885CREBBP 393/4885TP53 713/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | GRM7 2801/4885CREBBP 393/4885TP53 713/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | GRM7 1157/4885CREBBP 994/4885TP53 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.